Brief: Acasti Announces Completion Of Patient Enrollment In Pivotal Phase 3 Strive-On Safety Trial Of Gtx-104
Sept 25 (Reuters) - Acasti Pharma Inc ACST.O :
* ACASTI ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN
PIVOTAL
PHASE 3 STRIVE-ON SAFETY TRIAL OF GTX-104
Source text for Eikon: ID:nGNX889yxJ
Further company coverage: ACST.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grace Therapeutics
See all newsBrief: Grace Therapeutics - Selling Stockholders May Resell Up To 4,761,904 Shares Of Common Stock - SEC Filing
Grace Therapeutics Q1 net loss widens on impairment charges
Grace Therapeutics falls after FDA declines to approve stroke drug
NASDAQ RESUMED AT 01:57 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 01:52 PM